Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-245
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-9
   PubMed Web of Science ®Google Scholar
• Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9:348-56
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu B-C, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circulation 2011;4:313-20
   PubMed Web of Science ®Google Scholar
• Mantha S, Cabral K, Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Therapeut 2013;93:68-77
   PubMed Web of Science ®Google Scholar
• Boulanger L, Kim J, Friedman M, et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 2006;60:258-64
   PubMed Web of Science ®Google Scholar
• Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proceedings (Baylor University) 2001;9:193-5
   Google Scholar
• Biscup-Horn PJ, Streiff MB, Ulbrich TR, et al. Impact of an inpatient anticoagulation management service on clinical outcomes. Ann Pharmacother 2008;42:777-82
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19
   PubMed Web of Science ®Google Scholar
• Kim MM, Metlay J, Cohen A, et al. Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiol Drug Saf 2010;19:731-6
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Novel oral anticoagulants for atrial fibrillation. Curr Atherosclerosis Rep 2013;15:344
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
   PubMed Web of Science ®Google Scholar
• Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol 2013;167:1237-41
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hill J, Hess GP. Abstract 282: Dabigatran etexilate is associated with shorter hospital length of stay compared to warfarin in patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:A282
   Google Scholar
• Fonseca E, Walker DR, Hess GP. Abstract 258: Dabigatran etexilate is associated with shorter hospital length of stay and lower hospital costs compared to warfarin in treatment-naive, newly-diagnosed nonvalvular atrial fibrillation patients. Circ Cardiovasc Qual Outcomes 2013;6:A258
   Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645-53
   PubMed Web of Science ®Google Scholar
• M Health Information Systems – US. APR DRG Software. 2014
   Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Toronto Academic Press Inc., 1977:19-24
   Google Scholar
• Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Stat Simulat Comput 2009;38:1228-34
   Web of Science ®Google Scholar
• Harrington AR, Armstrong EP, Nolan PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81
   PubMed Web of Science ®Google Scholar
• Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110:845-51
   PubMed Web of Science ®Google Scholar
• Blomstrom Lundqvist C, Lip GYH, Kirchhof P. What are the costs of atrial fibrillation? Europace 2011;13(Suppl 2):ii9-12
   PubMed Web of Science ®Google Scholar